Logo

Perlegen to Conduct Second Genotyping Study for AstraZeneca

Jan 24, 2005

NEW YORK, Jan. 24 (GenomeWeb News) - Perlegen Sciences will conduct a second genotyping study for AstraZeneca, the Mountain View, Calif.-based company said today.

 

Under the agreement, Perlegen will determine SNPs in individuals with an undisclosed trait of interest as well as in controls.

 

One year ago, the two companies announced their first collaboration to study the genetics of myocardial infarction.

Breaking News
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.